Boeing’s (BA) recovery story is starting to change. For most of the past year, the stock traded on backlog and the idea that production would eventually normalize. Now, the focus is shifting. Investors are no longer asking whether demand exists. The order book is already there. The stock is down more than 22% since reporting Q4 earnings on Jan. 27, showing the market still isn’t convinced the turnaround is real. At the same time, the broader backdrop is changing. Airlines are still expanding routes ...

Core Insights - Millstreet Capital Management has established a new position in Diversified Energy Company, acquiring 1,378,421 shares valued at $19.96 million in the fourth quarter of 2025 [1][2]. Company Overview - Diversified Energy Company is a leading independent energy producer focused on mature, low-decline natural gas and oil assets across the United States, headquartered in Alabama [5]. - The company reported a total revenue of $1.61 billion and a net income of $341.1 million for the trailing twelve months (TTM) [4]. Financial Performance - The company generated $1.8 billion in full-year revenue, nearly $1 billion in adjusted EBITDA, and around $440 million in free cash flow, indicating a strong cash flow profile [6][7]. - As of the latest report, Diversified Energy Company shares were priced at $16.20, reflecting a 19% increase over the past year, slightly outperforming the S&P 500's 15% gain [7]. Investment Implications - The new position represents 4.5% of Millstreet's 13F reportable assets under management, indicating a strategic move towards a cash flow profile that contrasts with traditional growth holdings [6][7]. - The company is not focused on explosive production growth but rather on generating steady cash flow from mature assets, which aligns with current market conditions [6][7]. Operational Focus - Diversified Energy Company produces, markets, and transports natural gas, natural gas liquids, crude oil, and condensates, with primary operations in the Appalachian Basin and additional activities in Oklahoma, Texas, and Louisiana [8]. - The firm operates as an independent owner and operator of producing wells, generating revenue through the sale of hydrocarbons and associated midstream services [8].

Financial Data and Key Metrics Changes - In 2025, the company generated over $750 million in adjusted EBITDAX and reported a net loss of $41.4 million due to a non-cash impairment charge of $67.2 million from the sale of Canadian assets [6][27][28] - The company delivered production of 16,556 net revenue interest barrels of oil equivalent per day, exceeding guidance [27] - The SEC proved reserves decreased by 5% year-over-year to 43 million barrels of oil equivalent, but the PV-10 value increased by 8% to $410 million due to positive revisions [23][24] Business Line Data and Key Metrics Changes - The company divested all Canadian assets and expanded its Côte d'Ivoire position by becoming the operator with a 60% working interest in the Kossipo field [7][19] - In Gabon, the company began a phase three drilling program and successfully completed a full field maintenance shutdown [14][16] - The company drilled its first exploration well in Gabon since 2013, although it was unsuccessful [8] Market Data and Key Metrics Changes - The average SEC pricing was around $70 per barrel, impacting the company's reserves and financial metrics [23] - The company reported a significant improvement in collections from the Egyptian General Petroleum Corporation, reducing outstanding accounts receivable from $113 million to $31 million [32] Company Strategy and Development Direction - The company aims to grow production to 50,000 barrels of oil equivalent per day and has diversified its portfolio significantly over the past five years [8][43] - The strategy includes maintaining operational excellence, funding organic growth initiatives, and returning cash to shareholders [6][9][25] - The company is focused on developing high-quality assets in Côte d'Ivoire and Gabon while optimizing production in Egypt [44][46] Management's Comments on Operating Environment and Future Outlook - Management indicated that 2025 was a transitional year, with significant production uplifts expected from ongoing projects in 2026 and 2027 [9][25] - The company expressed confidence in its ability to execute its growth strategy and deliver value to shareholders despite trading at a low multiple of EBITDAX [41][47] Other Important Information - The company returned $26.5 million to shareholders through dividends in 2025 and has a robust capital program planned for 2026 [9][34] - The FPSO refurbishment in Côte d'Ivoire is on track, with the vessel expected to return to service in Q2 2026 [10][11] Q&A Session Summary Question: CapEx breakdown in Côte d'Ivoire - The majority of CapEx for Q1 is linked to the Gabon drilling program and FPSO finalization, with around $10 million allocated for Kossipo field development preparation [49][50] Question: Residual CapEx for drilling in Côte d'Ivoire in 2027 - The CapEx for Q4 2026 drilling program is expected to be between $30 million and $45 million [52] Question: Kossipo CapEx timeline - Major CapEx for Kossipo is anticipated to start in 2028, following the submission and approval of the field development plan [62] Question: Base Brent price forecast for guidance - The underlying Brent price assumption for 2026 is $65, with profit oil split benefiting from price increases [68] Question: Maintaining working interest in Kossipo and CI-705 - The company is comfortable with its current working interest in Kossipo and is evaluating the prospectivity of CI-705 [70][71] Question: CapEx in Côte d'Ivoire for FPSO and drilling - Approximately $50 million of the CapEx will be for FPSO hookup and recommissioning, with the balance for drilling [80] Question: Free cash flow application - Additional free cash flow will primarily be used to reduce debt rather than enhance shareholder returns due to high capital commitments [81]

Core Insights - Chubb Limited (CB) plans to propose a 5.2% increase in its dividend, which would result in an annual dividend of $4.08 per share, marking the 33rd consecutive year of dividend growth [1][6] Dividend and Yield - The current dividend yield for Chubb is 1.1%, significantly higher than the industry average of 0.3%, making it attractive for income-focused investors [2] - While Chubb's yield is higher than that of The Progressive Corporation (PGR), it is still lower than The Allstate Corporation (ALL) and The Travelers Corporation (TRV) [2] Business Strength and Strategy - Chubb is recognized as a leading property and casualty insurer and reinsurer, benefiting from a diverse portfolio of products and services [3] - The company's strategic focus on middle-market opportunities and ongoing investments in growth initiatives enhance its market reach [3] - Chubb's diversification across various geographies and business lines, including commercial and personal P&C, reinsurance, accident and health, and life insurance, supports consistent cash flow generation [3] - Earnings have improved by 19.7% over the last five years, indicating strong performance [3] Financial Position - Chubb maintains a solid balance sheet with ample liquidity, supporting its strategic priorities [4] - In 2025, the company reported operating cash flow of $12.8 billion and adjusted operating cash flow of $13.9 billion, reflecting a strong capital position [4][6] Payout Strategy - Chubb follows a conservative payout strategy with a dividend payout ratio of just 16%, providing financial flexibility for future increases [5] - This low payout ratio positions the company to sustain its long track record of annual dividend growth while supporting long-term shareholder returns [5]

Financial Data and Key Metrics Changes - In Q4 2025, contract sales declined by 4% year-over-year, with Adjusted EBITDA at $186 million [9][20] - For the full year, contract sales totaled $1.8 billion, down 3% from the previous year, with Adjusted EBITDA at $751 million [9][20] - VPG decreased by 60 basis points year-over-year, while tours were down 3% [20][21] - Total owner sales declined by 2% year-over-year, although owner VPG increased for the first time since 2024 [21] Business Line Data and Key Metrics Changes - Commercial rentals profit decreased by 26% to $25 million due to higher inventory costs [23] - Management and exchange profit increased by 9% to $92 million, while financing profit rose by 10% to $53 million [23] - Development profit declined by 8% to $94 million, with product cost as a percentage of development revenue decreasing by 90 basis points [22][23] Market Data and Key Metrics Changes - Sales were up in Las Vegas, Hilton Head, and Myrtle Beach, but declines were noted in Orlando, Hawaii, and Asia Pacific [20] - International sales were down 10% year-over-year [20] Company Strategy and Development Direction - The company is focused on improving profitability and free cash flow, emphasizing operational performance and disciplined capital allocation [11][14] - A strategic decision was made to reduce tours in the Asia Pacific region to enhance profitability and cash flow [13] - The company aims to monetize non-core assets, with a target of generating $200 million-$250 million from asset sales over the next two years [15][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in the first half of the year but expressed optimism about seeing benefits from strategic changes in the second half [18] - The company is committed to fostering a growth-oriented culture and improving cash flow and profitability [17][18] Other Important Information - The company ended Q4 with $3.2 billion in net corporate debt and repaid $575 million in convertible notes [23] - Non-cash impairments of $546 million were recorded in Q4, affecting inventory and goodwill [24] Q&A Session Summary Question: Sales force commentary and rebuilding efforts - Management noted that approximately 1,000 sales executives are currently in the system, with efforts to recruit back top performers who had left [34][36] Question: Vacation ownership business and VPG initiatives - Management discussed investments in training new hires and improving tour quality to enhance VPG [45][46] Question: Long-term EBITDA target and growth strategy - Management emphasized a focus on cost structure and growth opportunities, aiming for a culture of growth to drive EBITDA [53][54] Question: Technology initiatives and digital transformation - Management highlighted ongoing modernization spending, particularly in technology and digital capabilities, to enhance customer engagement [63][64] Question: Owner growth and upgrade potential - Management indicated that growing the owner base and enhancing engagement with existing owners are key to sustainable growth [99]

2025 EARNINGS: FULL YEAR and 4Q RESULTS FEBRUARY 26, 2026 © Montrose Environmental Group, Inc. 1 DISCLOSURES SAFE HARBOR Statements contained herein and in the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "intend," "expect", and "may", and other similar expressions that pr ...

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $154.2 million, consisting of $146 million from Attruby net product revenue, compared to $5.9 million for the same period last year, reflecting a significant increase of $148.3 million [31][32] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, marking an increase of $280.2 million [32][34] - Cash burn for the year was $446 million, with a decline in cash burn noted in Q4 relative to Q3, driven by rising revenues and improving operating leverage [6][10] Business Line Data and Key Metrics Changes - Attruby's net product revenue for Q4 was $146 million, contributing to a total of $362.4 million for the year, reflecting broad-based growth across market segments [23][31] - New patient growth for Attruby accelerated to 7,804 new patient starts in Q4, indicating strong commercial momentum [23][24] Market Data and Key Metrics Changes - Attruby achieved over 25% market share in the ATTR cardiomyopathy market as of December 31, 2025, with continued growth in unique patient prescriptions [17][23] - The company anticipates that its pipeline will begin generating cash in late 2027 and become a cash generation engine by 2028, projecting over $600 million in profit by that year [7][8] Company Strategy and Development Direction - The company is transitioning from a cash-consuming business to one that generates significant cash flows, with a focus on launching three additional products in late 2026 or early 2027 [5][11] - The strategy emphasizes establishing a best-in-class commercial engine for genetic disease therapies, with a commitment to R&D efficiency and organic growth rather than M&A [52][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the intrinsic value of the company, despite recent stock price volatility, attributing the disconnect to uncertainty surrounding the Tafamidis IP situation [10][80] - The company is focused on executing against its milestones and believes that its fundamentals have strengthened commercially, clinically, and strategically [10][11] Other Important Information - The company ended the year with a cash position of $587.5 million and completed the issuance of $632.5 million in convertible notes, providing significant cash runway for future operations [35] - Management highlighted the importance of differentiating Attruby's clinical profile and market positioning, asserting that it remains confident in its long-term value despite potential generic competition [80] Q&A Session Summary Question: What are the key drivers behind Attruby's consistent growth despite competitors slowing down? - Management attributed growth to a strong field team, superior clinical data, and a disciplined focus on patient and healthcare professional needs [40][41] Question: When will significant real-world data be available to establish clinical differentiation? - Management indicated that real-world evidence should be available by the end of the calendar year, focusing on early impact and specific patient populations [50] Question: How does the company plan to use incremental free cash flow in the future? - The company intends to reinvest in R&D and potentially consider share buybacks or dividends if unable to capture the intrinsic value of its assets [53] Question: What is the competitive landscape for infigratinib compared to other therapies? - Management believes infigratinib is best-in-class, with a favorable balance of efficacy and safety, setting a new standard in achondroplasia treatment [71] Question: What is the company's perspective on Tafamidis IP and its impact on Attruby? - Management views the Tafamidis IP debate as a sideshow, asserting that Attruby's clinical differentiation will sustain its market position regardless of generic competition [80]

Core Insights - The fleet utilization for January 2026 was reported at 100%, indicating strong operational performance across the vessels [1] - Safe Caledonia achieved 100% commercial uptime at the Captain Field in the UK, with a new Letter of Intent (LoI) from Ithaca Energy for a 6-month firm contract starting in Q2 2027 [2][3] - The company aims to capture strong market demand to grow its backlog at higher day rates while focusing on operational efficiencies and cost reductions for revenue growth and long-term value creation [4] Vessel Performance - Safe Eurus, Safe Notos, and Safe Zephyrus operated at near 100% commercial uptime in Brazil during January 2026 [1] - Safe Boreas is currently receiving full day rates and is awaiting the start of a 15-month firm period, expected to commence in Q1 2026 [2] Strategic Outlook - The company is evaluating opportunities to bridge the gap until the start of the 2027 contract linked to the LoI with Ithaca Energy, as well as potential contracts for 2028 and beyond [3] - The CEO of Prosafe emphasized the commitment to operational efficiencies and capturing market opportunities to enhance revenue and cash flow generation [4]

Core Viewpoint - Northern Trust Corporation is expected to report increased earnings and revenues for the fourth quarter of 2025, driven by higher net interest income and increased loan demand, despite facing challenges such as elevated expenses and asset quality risks [2][6]. Financial Performance Expectations - Analysts estimate an EPS of $2.37 and revenue of $2.06 billion for the upcoming quarterly earnings report [1]. - Growth in earnings and revenues is anticipated due to stabilizing funding costs and a rise in asset servicing fees [2]. Challenges and Risks - The company faces challenges including elevated expenses and risks related to asset quality, particularly non-performing assets [3][6]. - Concerns regarding financial leverage are highlighted by a debt-to-equity ratio of 1.21, indicating reliance on debt for financing [5]. Historical Performance - Northern Trust has a history of exceeding earnings estimates, as evidenced by its previous quarter's earnings surprise driven by increased net interest income and higher total assets under custody and management [3][6]. Market Position and Valuation - The stock is recognized as a top-ranked momentum stock by Zacks Investment Research, suggesting potential for market outperformance [4][6]. - The company's P/E ratio is 15.78 and price-to-sales ratio is 1.89, reflecting investor confidence, although a current ratio of 0.50 indicates potential challenges in covering short-term liabilities [4]. Cash Flow Concerns - Negative enterprise value to sales and operating cash flow ratios, at -0.97 and -5.56 respectively, may signal valuation and cash flow generation issues [5].

Bioventus Conference Call Summary Company Overview - **Company**: Bioventus - **Industry**: Healthcare, specifically in pain treatments, surgical solutions, and restorative therapies - **Annual Revenue**: Over $550 million - **Market Opportunity**: Over $6 billion across its portfolio [3][4] Core Business and Growth Drivers - **Core Business**: Comprises HA, bone graft substitutes, and fracture care, generating significant cash flow and high margins [6] - **Expansion Platform**: Includes ultrasonics and international markets, expected to contribute significantly to revenue growth [6][12] - **Emerging Growth Platform**: Focuses on peripheral nerve stimulation (PNS) and platelet-rich plasma (PRP), with PNS projected to grow at around 24% and PRP over 10% [7][9] - **Revenue Contribution**: By 2026, PNS and PRP are expected to contribute 200 basis points of growth [10] Financial Performance - **Gross Margin**: Peer-leading gross margin in the mid-70s% [15] - **EBITDA Margin**: Expanded by roughly 700 basis points [4] - **Operating Cash Flow**: Over $100 million generated in the last two years, with expectations for cash flow to double in 2025 [5][34] - **Debt Reduction**: Debt reduced to below $300 million, with a leverage ratio below 2.5 times [16] Strategic Initiatives - **Investment Focus**: Disproportionate investment in expansion and emerging platforms, including PNS sales organization and international sales resources [13][14] - **International Expansion**: Targeting EMEA and APAC regions with a disciplined approach to market entry [29][30] - **M&A Strategy**: High bar for M&A, focusing on synergistic opportunities that meet strong financial metrics [17][32] Market Position and Competition - **PNS Technology**: Unique advantages include being the only technology designed for peripheral nerves, with a full launch expected soon [8][22] - **Ultrasonics**: Aiming to establish this technology as the standard of care in spinal surgery through education and marketing [25][26] - **PRP Market**: Positioned to leverage existing HA salesforce, emphasizing customization and efficiency in treatment [9][27] Macroeconomic Considerations - **Tariff and FX Headwinds**: Anticipated $1-$2 million in tariffs for 2026, with a proactive management approach to overcome these challenges [35][36] Conclusion - **Future Outlook**: Bioventus is positioned for significant growth with a strong foundation, focusing on expanding its portfolio and enhancing profitability while managing financial discipline [18]